Recorded BCN webcasts provide timely and clinically relevant information on a variety of breast cancer topics. TME Breast Care Network doctors discussed recent clinical findings.
Recorded: December 4, 2018
Leading breast cancer experts Drs. Rakesh Patel and Pat Whitworth, along with PreludeDx Chief Scientific Officer and Founder, Dr. Troy Bremer, reviewed the latest predictive data supporting Prelude DCISionRT and discussed how DCISionRT is changing the way DCIS is managed today.
With 60,000 new pure DCIS patients diagnosed annually in the US, Drs. Rick Brown and James Pellicane offer insights as to how they use this test in their practice when counseling DCIS patients. Currently 77% of DCIS patients have breast conserving surgery (BCS), but only 66% of these continue with radiation therapy (RT). The point of this test is to determine which patients will truly benefit from RT, and to avoid “the overtreatment of all patients in order to not undertreat a few”.
DCISionRT® is a risk assessment test for patients with DCIS that predicts radiation therapy benefit with Level 1B clinical evidence. It provides a woman’s recurrence risk after breast conserving surgery alone and with the addition of radiation therapy. DCISionRT combines molecular biology with key clinicopathologic factors and was developed specifically for DCIS. The study presented in this webcast showed that when using traditional clinical pathologic factors, 59% of the low risk patients would have benefitted from RT, while 29% of the high risk patients would not. The doctors felt that this test helped patients feel more confident about their RT decision because it was personalized to them and not just in general.
Recorded: November 12, 2018
Pat Whitworth and Michael Alvarado hosted a discussion with a panel of TME breast surgeons and Rick Baehner M.D., VP of Development Oncology and Pathology at Genomic Health and Assistant Professor of Pathology at UCSF. The panel focused on ways to implement molecular testing for DCIS in routine practice. The panelists also discussed how to educate DCIS patients regarding risk of recurrence and potential radiation benefit using the Oncotype DCIS Score™.
The test reports individualized risk of recurrence and invasive recurrence by integrating DCIS Score, plus patient-age-at-diagnosis, plus size of tumor-- all of which impact recurrence (but not overall survival). The clinicopathologic factors of age and size were integrated with the DCIS Score™ result to provide a refined estimate of the 10-year risk of local recurrence after breast-conserving surgery to help guide treatment decision making.
This webcast also provided an overview of the validation and data supporting the Oncotype DX® Breast DCIS Score™ test, including the latest analysis of the ECOG E5194 and Ontario DCIS cohort studies.
Recorded: October 17, 2018
This recorded webcast shares how the MINDACT trial data shows how best to utilize the MammaPrint genomic test in daily practice. Dr. Pellicane discusses how MammaPrint determines the risk of distant recurrence and how to reduce that risk by offering chemotherapy to those patients who will benefit from it while not harming patients who can safely avoid chemotherapy. MINDACT included node positive patients in the study, making MammaPrint the only test integrated in the ASCO and NCCN guidelines that includes node positive patients. From this data Dr. Audeh shows that node positive (1-3) but genomic low risk patients had no benefit from chemotherapy. He also discusses MammaPrint ultralow patients that may do well without even Endocrine therapy.
Recorded: October 10, 2018
This recorded webcast by Dr. Christy Russel and moderated by Drs. Beitsch & Whitworth, first shows those genomic tests that can be used to guide chemotherapy decisions and those that are prognostic for the purpose of avoiding chemotherapy. More in-depth, is the data from the TAILORx study that shares clinical findings and relevance of Oncotype Dx recurrence scores of 11-25 with a lively discussion regarding therapy for these patients.
Recorded: October 5, 2018
This recorded webcast shares the clinical trial results behind the EndoPredict (Myriad) test that is one of 5 genomic tests in the ASCO approved guidelines. Used to predict the 10 year recurrence rate for HR+HER2 negative patients, the expert panel discusses when and why they order this test